Canadian Journal of Gastroenterology and Hepatology (Jan 2015)

Clinicians’ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease

  • Brian Bressler,
  • Remo Panaccione,
  • Richard N Fedorak,
  • Ernest G Seidman

DOI
https://doi.org/10.1155/2015/852723
Journal volume & issue
Vol. 29, no. 7
pp. 369 – 372

Abstract

Read online

BACKGROUND: Objective monitoring of the severity of inflammation in patients with inflammatory bowel disease (IBD) is an essential part of disease management. However, repeat endoscopy to define extent and severity of inflammation is not practical. Fecal calprotectin (FC) is a biomarker that can be used as a surrogate test to distinguish inflammatory from noninflammatory gastrointestinal disease.